---
title: "Psilocybin (COMP360) in Treatment-resistant depression: COMP001"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: COMP001. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 80 evidence topics quoted from 28 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence/comp001"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: COMP001

<a id="heading-3.1.3"></a>

## 3.1.3 COMP001

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Registered study purpose

> “The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a dose-ranging study”

Source: [ClinicalTrials.gov NCT03775200](https://clinicaltrials.gov/study/NCT03775200)

<a id="topic-3.1.3.1-2"></a>

#### Protocol objectives: dose selection and superiority over 1 mg

> “The main purpose of this study is to allow COMPASS to determine the optimal dose of psilocybin, either 10 mg or 25 mg.”
> “The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg or 10 mg) compared to 1 mg, administered under supportive conditions to adult participants with TRD, in improving depressive symptoms, as assessed by the change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from Baseline.”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="topic-3.1.3.1-3"></a>

#### Company statement of the trial objective

> “The objective of the randomised, controlled, double-blind phase 2b study was to understand the efficacy and safety of a single dose of investigational COMP360 psilocybin (25mg or 10mg), compared to 1mg, in patients with TRD.”
> “The objective of the trial was to find the appropriate dose for a larger, pivotal phase 3 programme, which COMPASS expects to begin in 2022.”

Source: [COMPASS Pathways NEJM publication release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-announces-publication-of-phase-2b-study-of-COMP360-psilocybin-therapy-for-treatment-resistant-depression-in-The-New-England-Journal-of-Medicine/default.aspx)

<a id="topic-3.1.3.1-4"></a>

#### Role in the new drug application

> “Robust NDA submission supported by data from two highly statistically significant Phase 3 trials and a Phase 2b study that each met its primary endpoint and involved a total of more than 1,000 participants living with highly chronic TRD”

Source: [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Study dates and identifiers

| Item | Registry record |
| --- | --- |
| Other study ID | “COMP001” |
| Study start (actual) | “2019-03-01” |
| Primary completion (actual) | “2021-07-30” |
| Study completion (actual) | “2021-09-27” |
| Results first posted | “2023-04-24” |

Source: [ClinicalTrials.gov NCT03775200](https://clinicaltrials.gov/study/NCT03775200)

<a id="topic-3.1.3.2-2"></a>

#### First and last participant visits

> “First patient first visit: 1 March 2019”
> “Last patients last visit: 27 September 2021”

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="topic-3.1.3.2-3"></a>

#### Sites and countries: company statement

> “In 2021, we completed a Phase 2b international multi-site, randomized, controlled, double-blind, dose-finding clinical trial to assess the safety and efficacy of active doses of COMP360 (10mg or 25mg) compared with 1mg COMP360 in 233 patients suffering with TRD, across 22 trial sites in 10 countries in North America and Europe.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.2-4"></a>

#### Sites: registry record

> “This study has 25 locations”

Source: [ClinicalTrials.gov NCT03775200](https://clinicaltrials.gov/study/NCT03775200)

<a id="topic-3.1.3.2-5"></a>

#### Enrollment by country

| Country | 25 mg | 10 mg | 1 mg | Total |
| --- | --- | --- | --- | --- |
| United States | “32” | “32” | “32” | “96” |
| Netherlands | “17” | “16” | “17” | “50” |
| United Kingdom | “11” | “10” | “12” | “33” |
| Spain | “5” | “6” | “5” | “16” |
| Ireland | “3” | “3” | “5” | “11” |
| Denmark | “3” | “2” | “3” | “8” |
| Czechia | “3” | “2” | “2” | “7” |
| Canada | “2” | “2” | “2” | “6” |
| Germany | “2” | “2” | “0” | “4” |
| Portugal | “1” | “0” | “1” | “2” |

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="topic-3.1.3.2-6"></a>

#### Timing of topline announcement and publication

> “Data from the phase 2b trial was announced in November and December 2021, and presented at the American Psychiatric Association annual meeting in New Orleans in May 2022.”

Source: [COMPASS Pathways NEJM publication release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-announces-publication-of-phase-2b-study-of-COMP360-psilocybin-therapy-for-treatment-resistant-depression-in-The-New-England-Journal-of-Medicine/default.aspx)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Randomized, double-blind, dose-controlled design

> “In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

<a id="topic-3.1.3.3-2"></a>

#### Registered design details

| Item | Registry record |
| --- | --- |
| Phase | “Phase 2” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |

Source: [ClinicalTrials.gov NCT03775200](https://clinicaltrials.gov/study/NCT03775200)

<a id="topic-3.1.3.3-3"></a>

#### Protocol design and visit schedule

> “This is a Phase 2, international multicentre, randomised, fixed-dose, double-blind trial.”
> “Participants will be seen at the clinic for Screening (V1 plus a minimum of 3 safety visits), Baseline (V2, Day -1), Day 0 (V3, Dosing), Day 1 (V4), Week 1 (V5), Week 2 (V6), Week 3 (V7), and Week 12 (V10).”
> “Participants will also be contacted for follow-up at Week 6 (V8) and Week 9 (V9).”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="topic-3.1.3.3-4"></a>

#### Preparation, administration, and follow-up sessions

> “Prior to administration, participants received at least one, and up to three, preparatory sessions with an assigned healthcare professional, in order to be informed and prepared for the COMP360 psilocybin session.”
> “Participants received two post-administration follow-up sessions with their healthcare professionals in which the psychedelic experience was discussed.”
> “Participants were followed for up to 12 weeks, with a visit the day after administration followed by weekly visits for the first three weeks, and visits every three weeks for the remaining nine weeks.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.3-5"></a>

#### Screening period and antidepressant taper

> “Those who meet the eligibility criteria will enter the screening period, which will last between 3 and 6 weeks.”
> “During the screening period, participants who are on antidepressant medications will be expected to complete the taper at least 2 weeks prior to Baseline (V2).”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Registered eligibility criteria

| Item | Registry record |
| --- | --- |
| Inclusion | “Diagnosis of TRD” |
| Exclusion | “Other comorbidities” |
| Ages eligible | “18 Years and older” |
| Healthy volunteers | “No” |

Source: [ClinicalTrials.gov NCT03775200](https://clinicaltrials.gov/study/NCT03775200)

<a id="topic-3.1.3.4-2"></a>

#### Company definition of treatment-resistant depression

> “We define patients with TRD as those who meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, or DSM-5, diagnostic criteria for a single or recurrent episode of MDD without psychotic features, who have not responded to an adequate dose and duration of two, three, or four pharmacological treatments for the current episode of depression.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.4-3"></a>

#### Inclusion criteria: protocol

| Criterion | Quoted protocol text |
| --- | --- |
| Age | “18 years of age or older at Screening (V1).” |
| Diagnosis | “At least moderate MDD (single or recurrent episode as informed by DSM-5; if single episode, duration of ≥ 3 months and ≤ 2 years) based on medical records, clinical assessment and documented completion of the version 7.0.2 MINI.” |
| Symptom severity | “HAM-D-17 (17-item) score ≥ 18 at Screening (V1) and at Baseline (V2).” |
| Treatment resistance | “Failure to respond to an adequate dose and duration of 2, 3, or 4 pharmacological treatment for the current episode as determined through the MGH-ATRQ” |
| Augmentation | “Augmentation with an add-on treatment counts as a second treatment, provided it is approved for the adjunctive treatment of MDD in that country.” |
| Borderline personality screen | “McLean Screening Instrument for Borderline Personality Disorder < 7 at Screening (V1).” |
| Antidepressant discontinuation | “Have successfully discontinued all antidepressant medications at least 2 weeks prior to Baseline (V2).” |

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="topic-3.1.3.4-4"></a>

#### Exclusion criteria: protocol

| Criterion | Quoted protocol text |
| --- | --- |
| Psychiatric comorbidity | “Current or past history of schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, borderline personality disorder, or any serious psychiatric comorbidity as assessed by medical history and a structured clinical interview (version 7.0.2 MINI).” |
| Prior ECT or ketamine | “Prior electroconvulsive therapy and/or ketamine for current episode.” |
| Substance use | “Current (within the last year) alcohol or substance abuse as informed by DSM-5 at Screening (V1).” |
| Suicide risk | “Significant suicide risk as defined by (1) suicidal ideation as endorsed on items 4 or 5 on the C-SSRS within the past year, at Screening or at Baseline, or; (2) suicidal behaviors within the past year, or; (3) clinical assessment of significant suicidal risk during subject interview.” |
| Psychedelic exposure | “exposure to psilocybin within the past year and use of psychedelics, such as ayahuasca, during the current depressive episode” |
| Pregnancy | “Women who are pregnant, nursing, or planning a pregnancy.” |
| Cardiovascular | “Cardiovascular conditions: recent stroke (< 1 year from signing of ICF), recent myocardial infarction (< 1 year from signing of ICF), hypertension (blood pressure > 140/90 mmHg) or clinically significant arrhythmia within 1 year of signing the ICF.” |
| Diabetes | “Uncontrolled insulin-dependent diabetes.” |
| Seizures | “Seizure disorder.” |

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="topic-3.1.3.4-5"></a>

#### Prior psilocybin experience cap

> “The majority of participants will have no prior exposure to psilocybin or so-called magic mushrooms; however, to reflect the prevalence of experience in general population, we will allow up to 10% of participants with prior recreational experience with psilocybin or magic mushrooms.”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Investigational product by arm

| Arm | Quoted protocol text |
| --- | --- |
| All arms | “Single 5-capsule oral psilocybin dose:” |
| 25 mg | “25 mg treatment: 5 × 5 mg capsules” |
| 10 mg | “10 mg treatment: 2 × 5 mg capsules and 3 × placebo capsules” |
| 1 mg | “1 mg treatment: 1 × 1 mg capsule and 4 × placebo capsules” |

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="topic-3.1.3.5-2"></a>

#### Administration session

> “The psilocybin administration session (V3, Day 0) will last approximately 6 hours and will be supported by a trained therapist.”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

> “During the COMP360 psilocybin session, a single dose of COMP360 was administered to participants.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.5-3"></a>

#### Psychological support model

> “which randomized 233 adults with TRD in 1:1:1 ratio to a single fixed-dose (25 mg, 10 mg, or 1 mg) of COMP360 that was administered with a well-defined psychological support model that emphasizes safety and self-directed enquiry”
> “As part of the COMP360 treatment, psychological support was provided to ensure the participants’ physical and psychological safety and consisted of three phases: preparation, administration, and integration.”

Source: [Dougherty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12226623/)

<a id="topic-3.1.3.5-4"></a>

#### Antidepressant washout before and after dosing

> “Participants who were on serotonergic medications were required to taper off their medicine at least two weeks prior to the baseline (Day -1) visit.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “All participants will be asked to remain off their antidepressant medications for at least 3 weeks following the psilocybin session until the primary endpoint assessment, or longer.”
> “These medications are not to be reintroduced to the participant until after V7 (Week 3).”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="topic-3.1.3.5-5"></a>

#### Rescue medication

> “Rescue medications may be used during and after the psilocybin session.”
> “Benzodiazepine anxiolytics is the pharmacological intervention of choice in case of acute psychological distress”
> “Antipsychotic medications (eg, risperidone) should be available in the event that an adverse reaction escalates to unmanageable psychosis.”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Montgomery-Åsberg Depression Rating Scale Total Score as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Primary endpoint definition

> “The primary end point was the change from baseline to week 3 in the total score on the Montgomery-Åsberg Depression Rating Scale (MADRS; range, 0 to 60, with higher scores indicating more severe depression).”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

> “MADRS is a clinician-rated scale measuring depression symptom severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of between 0 to 60; higher scores denote greater severity.”

Source: [ClinicalTrials.gov NCT03775200](https://clinicaltrials.gov/study/NCT03775200)

<a id="topic-3.1.3.6.1-2"></a>

##### Company rationale for the scale

> “MADRS, as assessed by independent raters in native language, is a widely accepted assessment of mood disorders.”
> “This variable was also being analyzed for change from baseline to Day 2, weeks 1, 6, 9 and 12.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.6.1-3"></a>

##### Independent remote blinded rating

> “MADRS evaluations will be performed by an independent remote rater who is blinded to the participant’s treatment assignment at Baseline, Day 1, and Weeks 1, 3, 6, 9, and 12 (V2, V4, V5, V7, V8, V9, and V10, respectively).”
> “The structure of the telephone-based interview will be controlled through the use of The Structured Interview Guide for the MADRS (SIGMA)”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

> “The MADRS was assessed by independent raters who were remote from the trial site, and blind to intervention and study design, effectively creating a triple blind.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.6.1-4"></a>

##### Scale construction and sensitivity to change

> “The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described.”
> “Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.”

Source: [Montgomery and Asberg (1979)](https://pubmed.ncbi.nlm.nih.gov/444788/)

<a id="topic-3.1.3.6.1-5"></a>

##### Regulatory acceptance as a primary endpoint

> “Clinician-rated outcome measures are the current standard for assessing efficacy in”
> “To date, the FDA has accepted the following as primary endpoints in phase”
> “Montgomery Asberg Depression Rating Scale”

Source: [FDA (2018)](https://www.fda.gov/media/113988/download)

> “Acceptable scales to determine symptomatic improvement include the Hamilton Rating Scale of Depression (HDRS), preferably the 17-item scale, and the Montgomery-Asberg Depression Rating Scale (MADRS), however other validated scales might be acceptable as well.”
> “For rapid acting antidepressants it is anticipated that specific scales, other than the most commonly used MADRS, will be developed and validated, in order to be able to fully capture the rapid onset of effect.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-3.1.3.6.1-6"></a>

##### Timing of the primary endpoint for a rapid-acting treatment

> “Efficacy generally should be demonstrated within 1 week for a rapid-acting”
> “Durability of effect beyond the initial response should be characterized.”

Source: [FDA (2018)](https://www.fda.gov/media/113988/download)

<a id="topic-3.1.3.6.1-7"></a>

##### Clinically meaningful change in treatment-resistant depression

> “Clinically meaningful changes in CGI‐S scores after 28 days corresponded to 6‐, 4‐, and 3‐point changes from baseline on the MADRS, SDS, and PHQ‐9, respectively.”
> “Similarly, a 2‐point CGI‐S score change (clinically substantial change) corresponded to a 12‐, 8‐, and 6‐point change on the MADRS, SDS, and PHQ‐9, respectively.”

Source: [Turkoz et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7986932/)

<a id="topic-3.1.3.6.1-8"></a>

##### Minimal important difference estimates

> “For both the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Beck Depression Inventory II (BDI-II), MID estimates range between 3 and 9 points, with estimates of 3-6 points likely being the most accurate.”

Source: [Hengartner and Plöderl (2022)](https://pubmed.ncbi.nlm.nih.gov/33593736/)

> “MCID estimates for MADRS ranged from 1.6 to 1.9.”

Source: [Duru and Fantino (2008)](https://pubmed.ncbi.nlm.nih.gov/18377706/)

<a id="topic-3.1.3.6.1-9"></a>

##### Response and remission thresholds

> “Secondary end points included response at week 3 (≥50% decrease from baseline in the MADRS total score), remission at week 3 (MADRS total score ≤10), and sustained response at 12 weeks (meeting response criteria at week 3 and all subsequent visits).”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

> “Our results confirm the validity of the commonly used measures for response in MDD trials: a CGI-I score of 2 ('much improved') corresponded to a percentage MADRS reduction from baseline of 48-57%, and a CGI-I score of 1 ('very much improved') to a reduction of 80-84%.”

Source: [Leucht et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28068617/)

> “On the basis of a narrow definition of remission, which requires a complete absence of clinically significant symptoms of depression, the optimal MADRS cutoff was < or = 4. On the basis of a broader definition, the optimal cutoff was < or = 9.”

Source: [Zimmerman et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15003068/)

> “In MDD a 50% improvement of a patient on a usual rating scale is accepted as a clinically relevant response.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-3.1.3.6.1-10"></a>

##### Key secondary endpoint hierarchy and multiplicity control

> “To control the overall Type I error rate a sequential test procedure will be applied across the primary and key secondary efficacy endpoints for both COMP360 doses (25 mg and 10 mg) following the hierarchy specified below, with all testing done at the 0.05 alpha level:”
> “Primary endpoint, change in MADRS total score from baseline to week 3 (25 mg vs 1 mg)”
> “Primary endpoint, change in MADRS total score from baseline to week 3 (10 mg vs 1 mg)”

Source: [COMPASS Pathways COMP001 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/SAP_001.pdf)

<a id="topic-3.1.3.6.1-11"></a>

##### Time-to-event secondary endpoints in the protocol

> “Time to event measures: restart antidepressant medication for any reason, restart medication for continuing depressive symptoms, and relapse from a previously recovered state (clinical judgement, supported by the QIDS-SR-16).”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Planned enrollment and power

> “216 participants will be randomised in a 1:1:1 ratio to receive 1 mg psilocybin, 10 mg psilocybin, or 25 mg psilocybin.”
> “The 6-point difference in average MADRS total score on a group level is supported by the pilot study with psilocybin”
> “and is within the range of potential differences that have been used to power other studies in major depression and TRD.”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

> “For this primary analysis, a sample size of 216 randomised participants (72:72:72) will provide 90% power at the alpha = 0.05 level to detect a 6-point difference in average MADRS total score between the optimal therapeutic dose of COMP360 and COMP360 1 mg, assuming the common standard deviation (SD) is 11.0.”

Source: [COMPASS Pathways COMP001 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/SAP_001.pdf)

<a id="topic-3.1.3.7.1-2"></a>

##### Actual enrollment: registry record

| Enrollment type | Participants |
| --- | --- |
| Actual | “233” |

Source: [ClinicalTrials.gov NCT03775200](https://clinicaltrials.gov/study/NCT03775200)

<a id="topic-3.1.3.7.1-3"></a>

##### Randomized participants by arm

> “A total of 79 participants were in the 25-mg group, 75 in the 10-mg group, and 79 in the 1-mg group.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

<a id="topic-3.1.3.7.1-4"></a>

##### Participants analyzed for the primary endpoint

| Analysis | 25 mg | 10 mg | 1 mg |
| --- | --- | --- | --- |
| Full analysis set (primary) | “79” | “75” | “79” |
| Per-protocol set (sensitivity) | “77” | “65” | “68” |

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

##### Analysis set definitions

> “The Randomised Analysis Set: All randomised participants, whether or not they receive study drug.”
> “The Safety Analysis Set: All randomised participants who receive study drug.”
> “The Full Analysis Set (FAS): All participants randomised who receive study drug and have at least 1 post-dose efficacy assessment.”
> “The Per-Protocol (PP) Analysis Set: All participants in the FAS who do not have a protocol deviation that is thought to significantly affect the integrity of the participant’s efficacy data.”

Source: [COMPASS Pathways COMP001 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/SAP_001.pdf)

<a id="topic-3.1.3.7.2-2"></a>

##### Changes to analysis sets from the protocol

> “modified Intent-to-Treat was removed”
> “Full Analysis Set definition updated to match the modified Intent-to-Treat definition”

Source: [COMPASS Pathways COMP001 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/SAP_001.pdf)

<a id="topic-3.1.3.7.2-3"></a>

##### Primary and secondary estimands

> “The Hypothetical Strategy will be the primary estimand to best understand the clinical effects of COMP360 without the effects of participants taking new treatments for depression.”
> “The Treatment Policy will be the secondary estimand to understand the clinical effects of COMP360 versus inactive control including participants taking new treatment for depression if needed in both arms.”

Source: [COMPASS Pathways COMP001 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/SAP_001.pdf)

<a id="topic-3.1.3.7.2-4"></a>

##### Primary analysis model in the protocol

> “The primary efficacy endpoint (change from Baseline in MADRS total score at Week 3) will be evaluated with a mixed-effects model for repeated measures analysis.”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="topic-3.1.3.7.2-5"></a>

##### Analysis populations reported in the registry

> “The full analysis set includes all participants randomised who receive study drug and have at least 1 post-dose efficacy assessment.”
> “The per-protocol analysis set includes all participants in the Full Analysis Set who do not have a protocol deviation that is thought to significantly affect the integrity of the participant's efficacy data.”
> “The Safety Analysis Set included all randomised participants who received study drug.”

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### Participant flow: registry results

| Status | 25 mg | 10 mg | 1 mg |
| --- | --- | --- | --- |
| Started | “79” | “75” | “79” |
| Completed | “74” | “66” | “69” |
| Not completed | “5” | “9” | “10” |

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="topic-3.1.3.8.1-2"></a>

##### Completion and withdrawals: company statement

> “Overall, 209 patients completed the study; there were five withdrawals from the 25mg group, nine from the 10mg, and 10 from the 1mg.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

##### Demographics: registry results

| Characteristic | 25 mg | 10 mg | 1 mg | Total |
| --- | --- | --- | --- | --- |
| Participants | “79” | “75” | “79” | “233” |
| Age, mean (SD), years | “40.2(12.19)” | “40.6(12.76)” | “38.7(11.71)” | “39.8(12.19)” |
| Age 65 years or older | “3” | “2” | “2” | “7” |
| Female | “35” | “34” | “43” | “112” |
| Male | “44” | “41” | “36” | “121” |
| White | “70” | “72” | “73” | “215” |
| Asian | “4” | “3” | “5” | “12” |
| Black or African American | “4” | “0” | “1” | “5” |

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="topic-3.1.3.8.2-2"></a>

##### Baseline depression severity

> “The mean MADRS total score at baseline was 32 or 33 in each group.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

<a id="topic-3.1.3.8.2-3"></a>

##### Prior psilocybin experience

> “94% of the patients had no prior experience with psilocybin.”

Source: [COMPASS Pathways NEJM publication release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-announces-publication-of-phase-2b-study-of-COMP360-psilocybin-therapy-for-treatment-resistant-depression-in-The-New-England-Journal-of-Medicine/default.aspx)

<a id="topic-3.1.3.8.2-4"></a>

##### Baseline suicidality

> “Two thirds of the patients had previous thoughts of wishing to be dead, as assessed by a suicidality scale completed during patient screening; this included all patients reporting one of these adverse events, meaning that patients who experienced these events during the trial had said in patient screening that they had had suicidal thoughts prior to the trial.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “Suicidality was comparable between groups at Baseline.”

Source: [Marwood et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39427449/)

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

##### Primary endpoint: change in MADRS total score at Week 3

> “Least-squares mean changes from baseline to week 3 in the score were -12.0 for 25 mg, -7.9 for 10 mg, and -5.4 for 1 mg; the difference between the 25-mg group and 1-mg group was -6.6 (95% confidence interval [CI], -10.2 to -2.9; P<0.001) and between the 10-mg group and 1-mg group was -2.5 (95% CI, -6.2 to 1.2; P = 0.18).”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

<a id="topic-3.1.3.8.3-2"></a>

##### Primary endpoint: company statement

> “The Phase 2b study met its primary endpoint.”
> “The 25mg group vs the 1mg group showed a -6.6 difference on the MADRS depression scale at week 3 (p<0.001).”
> “The 10mg vs 1mg dose did not show a statistically significant difference at week 3.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.8.3-3"></a>

##### Observed MADRS change at Week 3: registry results

| Analysis set | 25 mg | 10 mg | 1 mg |
| --- | --- | --- | --- |
| Full analysis set, mean (SD) | “-12(12.98)” | “-8.9(10.94)” | “-6.8(11.10)” |
| Per-protocol set, mean (SD) | “-12(12.98)” | “-8.9(11.11)” | “-6.7(11.18)” |

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="topic-3.1.3.8.3-4"></a>

##### Onset of effect at Day 2

> “The 25mg group demonstrated statistical significance on the MADRS efficacy endpoint on the day after the COMP360 psilocybin administration, day 2 (p=0.002).”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.8.3-5"></a>

##### Response, remission, and sustained response

> “In the 25-mg group, the incidences of response and remission at 3 weeks, but not sustained response at 12 weeks, were generally supportive of the primary results.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

> “After a single 25mg dose of COMP360 psilocybin, in combination with psychological support, 29.1% of participants with TRD were in remission by week 3 (p<0.002)”
> “Double the number of patients who received a 25mg dose had a sustained response at week 12, compared to those who received 1mg (20.3% of patients in the 25mg group vs 10.1% in the 1mg group)”

Source: [COMPASS Pathways NEJM publication release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-announces-publication-of-phase-2b-study-of-COMP360-psilocybin-therapy-for-treatment-resistant-depression-in-The-New-England-Journal-of-Medicine/default.aspx)

<a id="topic-3.1.3.8.3-6"></a>

##### Post hoc analysis: antidepressant discontinuation before dosing

> “Antidepressant drug discontinuation was not related to worsening of depression severity before Baseline.”
> “Psilocybin treatment efficacy and the subjective psychedelic experience did not appear to be compromised by antidepressant drug discontinuation.”

Source: [Marwood et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39427449/)

<a id="topic-3.1.3.8.3-7"></a>

##### Post hoc analysis: psychedelic experience and outcome

> “The mean intensity of psychedelic effects was dose-related, but distributions of scores for different doses overlapped considerably.”
> “At the 25 mg dose, 5D-ASC dimensions Oceanic Boundlessness (Pearson correlation coefficient r = -0.508) and Visual Restructuralization (r = -0.516), and EBI (r = -0·637) were the variables with the strongest correlation to the Week 3 change from Baseline in MADRS score.”

Source: [Goodwin et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39706482/)

<a id="topic-3.1.3.8.3-8"></a>

##### Post hoc analysis: therapeutic alliance

> “Change from Baseline to Week 3 MADRS scores showed weaker correlations with pre-dosing therapeutic alliance (-0.178) than with measures of the psychedelic experience: EBI (-0.637), Oceanic Boundlessness (-0.508), and Visual Restructuralization (-0.516).”
> “The effects of the alliance itself on therapeutic efficacy were either limited or absent.”

Source: [Goodwin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41881122/)

<a id="topic-3.1.3.8.3-9"></a>

##### Post hoc analysis: pretreatment characteristics and the psychedelic experience

> “Dose was the strongest and most consistent predictor of the psychedelic experience.”
> “Some pretreatment characteristics contributed weakly to subjective experiences.”

Source: [Kirlić et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41362124/)

<a id="topic-3.1.3.8.3-10"></a>

##### Exploratory analysis: language-based prediction of response

> “Two multinomial logistic regression models were fit to predict responder status at week 3 and through week 12. Cross-validation of these models resulted in 85% and 88% accuracy and AUC values of 88% and 85%.”

Source: [Dougherty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12226623/)

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

##### Patient-reported measures assessed

> “Efficacy measures assessed patient-reported depression severity, anxiety, positive and negative affect, functioning and associated disability, quality of life, and cognitive function.”

Source: [Goodwin et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36740140/)

<a id="topic-3.1.3.8.4-2"></a>

##### Week 3 patient-reported outcomes

> “At Week 3, psilocybin 25 mg, compared with 1 mg, was associated with greater improvements from Baseline total scores in all measures. The 10 mg dose produced smaller effects across these measures.”
> “Three weeks after dosing, psilocybin 25 mg and, to a lesser degree, 10 mg improved measures of patient-reported depression severity, anxiety, affect, and functioning.”

Source: [Goodwin et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36740140/)

<a id="topic-3.1.3.8.4-3"></a>

##### Exploratory endpoints and multiplicity

> “Quality of life in participant EuroQoL (EQ)- 5 dimension-3 level scale (EQ-5D-3L) score change from Baseline to Week 3.”
> “The exploratory analyses for quality of life and wellbeing, functioning and associated disability, cognitive function, and anxiety are not hierarchical; there will be no correction for multiplicity in these analyses.”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### Overall adverse events

> “Adverse events occurred in 179 of 233 participants (77%) and included headache, nausea, and dizziness. Suicidal ideation or behavior or self-injury occurred in all dose groups.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

<a id="topic-3.1.3.8.5-2"></a>

##### Severity and timing of treatment-emergent adverse events

> “COMP360 was generally well tolerated, with more than 90% of treatment-emergent adverse events, or TEAEs, being mild or moderate in severity and greater than 77% of TEAEs occurring on the day of administration being resolved on the same day or the next day.”
> “179 patients reported at least one TEAE; the most common TEAEs across treatment groups (>10% overall incidence) were headache, nausea, fatigue, and insomnia.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.8.5-3"></a>

##### Serious adverse events through Week 12: registry results

| Event | 25 mg | 10 mg | 1 mg |
| --- | --- | --- | --- |
| Any serious adverse event | “5/79 (6.33%)” | “6/75 (8.00%)” | “1/79 (1.27%)” |
| Suicidal behaviour | “3/79 (3.80%)” | “0/75 (0.00%)” | “0/79 (0.00%)” |
| Intentional self-injury | “2/79 (2.53%)” | “2/75 (2.67%)” | “1/79 (1.27%)” |
| Suicidal ideation | “2/79 (2.53%)” | “2/75 (2.67%)” | “0/79 (0.00%)” |
| Drug withdrawal syndrome | “1/79 (1.27%)” | “0/75 (0.00%)” | “0/79 (0.00%)” |
| Depression | “0/79 (0.00%)” | “1/75 (1.33%)” | “0/79 (0.00%)” |
| Hospitalisation | “0/79 (0.00%)” | “1/75 (1.33%)” | “0/79 (0.00%)” |
| All-cause mortality | “0/79 (0.00%)” | “0/75 (0.00%)” | “0/79 (0.00%)” |

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="topic-3.1.3.8.5-4"></a>

##### Serious adverse events: company statement

> “There were 12 patients, 5 patients in the 25 mg group, 6 patients in the 10 mg group and 1 in the 1 mg group, who reported treatment-emergent serious adverse events, or TESAEs.”
> “These TESAEs included, among others, suicidal behavior, intentional self-injury, and suicidal ideation, which are regularly observed in a TRD patient population.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.8.5-5"></a>

##### Other adverse events with frequency of 5% or more: registry results

| Event | 25 mg | 10 mg | 1 mg |
| --- | --- | --- | --- |
| Any other adverse event | “60/79 (75.95%)” | “51/75 (68.00%)” | “50/79 (63.29%)” |
| Headache | “27/79 (34.18%)” | “16/75 (21.33%)” | “20/79 (25.32%)” |
| Nausea | “18/79 (22.78%)” | “7/75 (9.33%)” | “4/79 (5.06%)” |
| Fatigue | “12/79 (15.19%)” | “5/75 (6.67%)” | “7/79 (8.86%)” |
| Insomnia | “8/79 (10.13%)” | “11/75 (14.67%)” | “14/79 (17.72%)” |
| Anxiety | “7/79 (8.86%)” | “13/75 (17.33%)” | “3/79 (3.80%)” |
| Mood altered | “7/79 (8.86%)” | “3/75 (4.00%)” | “1/79 (1.27%)” |
| Dizziness | “6/79 (7.59%)” | “1/75 (1.33%)” | “1/79 (1.27%)” |
| Back pain | “6/79 (7.59%)” | “0/75 (0.00%)” | “3/79 (3.80%)” |
| Suicidal ideation | “5/79 (6.33%)” | “3/75 (4.00%)” | “4/79 (5.06%)” |
| Myalgia | “5/79 (6.33%)” | “2/75 (2.67%)” | “1/79 (1.27%)” |
| Panic reaction | “4/79 (5.06%)” | “1/75 (1.33%)” | “1/79 (1.27%)” |
| Euphoric mood | “4/79 (5.06%)” | “5/75 (6.67%)” | “4/79 (5.06%)” |
| Thinking abnormal | “0/79 (0.00%)” | “4/75 (5.33%)” | “0/79 (0.00%)” |

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="topic-3.1.3.8.5-6"></a>

##### Timing of suicidality events and dose-related events

> “On the day of COMP360 administration, headache, nausea, and dizziness were the most common adverse events where a dose-related increase in incidence was evident”
> “Suicidal ideation and intentional self-injury were seen in all treatment groups, as is common in TRD studies. Most cases occurred more than a week after the COMP360 psilocybin session. There was no mean worsening of suicidal ideation scores on the MADRS scale in any treatment group. Suicidal behaviours were reported at least one month after COMP360 administration for three non-responders in the 25mg arm”

Source: [COMPASS Pathways NEJM publication release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-announces-publication-of-phase-2b-study-of-COMP360-psilocybin-therapy-for-treatment-resistant-depression-in-The-New-England-Journal-of-Medicine/default.aspx)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary: functional unblinding, low-dose comparator without an active treatment, antidepressant washout, Week 3 primary endpoint

The authors state that interpretation is limited by the absence of an active comparator and the possibility of functional unblinding in participants who received a low dose, and that larger and longer trials, including comparison with existing treatments, are required. Published correspondence disputed the description of the trial as double-blind. The primary endpoint was at Week 3, and the authors state that in the 25 mg group, sustained response at 12 weeks was not generally supportive of the primary results. Participants tapered antidepressants at least two weeks before baseline and were asked to remain off them for at least 3 weeks after dosing; a commentary notes that many started other antidepressants after Week 3. The same commentary notes emergent suicidal ideation and behavior in the 25 mg and 10 mg groups and not in the 1 mg group, and the publication reports suicidal ideation or behavior or self-injury in all dose groups.

Source: [Goodwin et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36740140/); [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/); [Østergaard and Hieronymus (2023)](https://www.nejm.org/doi/full/10.1056/NEJMc2215459); [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm); [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf); [Mann (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9873942/)

<a id="topic-3.1.3.9-2"></a>

#### Authors' stated limitations: comparator and trial size

> “Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

> “Interpretation of this trial is limited by the absence of an active comparator and the possibility of functional unblinding in participants who received a low dose of psilocybin.”

Source: [Goodwin et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36740140/)

<a id="topic-3.1.3.9-3"></a>

#### Authors' stated limitations: secondary analyses

> “The existence of correlation does not establish causation and exploratory findings require further replication, preferably in larger independent samples.”

Source: [Goodwin et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39706482/)

> “Limitations of this study include that we were only able to analyze a cohort of 101 participants at 3 weeks and 90 individuals at 12 weeks.”

Source: [Dougherty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12226623/)

<a id="topic-3.1.3.9-4"></a>

#### Functional unblinding: published correspondence

> “The authors refer to their trial as a double-blind trial.”
> “This is hardly true for the trial”

Source: [Østergaard and Hieronymus (2023)](https://www.nejm.org/doi/full/10.1056/NEJMc2215459)

<a id="topic-3.1.3.9-5"></a>

#### Functional unblinding: sponsor-authored response

> “The intensity of psychedelic experience overlaps widely across doses and mitigates the risk of unblinding to dose.”

Source: [Goodwin et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39706482/)

<a id="topic-3.1.3.9-6"></a>

#### Functional unblinding and expectancy in psychedelic trials

> “While psychedelic RCTs have generally shown promising results, with large effect sizes reported, we argue that treatment effect sizes in psychedelic RCTs are likely over-estimated due to de-blinding of participants and high levels of response expectancy.”

Source: [Muthukumaraswamy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34038314/)

> “This increases the potential for bias due to functional unblinding of patients, therapists, monitors, or raters.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

> “Positive expectancy might lead to overestimation bias while disappointment with treatment (negative expectancy) might lead to symptom worsening or safety issues (nocebo effect).”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-3.1.3.9-7"></a>

#### Commentary: dose selection, psychedelic effects, and suicidality

> “The findings support use of drug plasma levels to optimize psilocybin doses and to analyze dose-dependent variance in clinical response, instead of using oral dose.”
> “Most side effects (nausea, headache) were comparable between the 10 mg and 25 mg dose groups, but surprisingly, the paper is silent about psychedelic effects even though it reports such effects lasted about 6 h after taking psilocybin.”
> “Of note, suicidal ideation and behavior history were comparable in all three dose groups prior to the study, but emergent suicidal ideation and behavior was observed in the 25 mg and 10 mg groups and not in the 1 mg group (employed as an active comparator instead of a placebo).”

Source: [Mann (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9873942/)

<a id="topic-3.1.3.9-8"></a>

#### Commentary: antidepressant restart after Week 3

> “Individuals who participated in the study were asked to stay off other psychotropic medications for the first 3 weeks and most complied.”
> “The 25 mg dose showed efficacy compared with 1 mg daily at 3 weeks, and this continued until 12 weeks, even though many patients started other antidepressants after week 3.”

Source: [Mann (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9873942/)

<a id="topic-3.1.3.9-9"></a>

#### Antidepressant washout before dosing

> “It has been suggested that the recent use and discontinuation of antidepressant drugs compromises the action of psilocybin.”
> “As evidence is only available from small or uncontrolled samples, this post hoc analysis investigated this using data from the largest, phase II, randomized controlled trial of psilocybin treatment to date.”

Source: [Marwood et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39427449/)

<a id="topic-3.1.3.9-10"></a>

#### Commentary on the therapeutic alliance analysis

> “While the authors conclude that alliance did not meaningfully contribute to treatment efficacy, we argue that this interpretation is not supported by the reported results, which are, in addition, shaped by methodological decisions that obscure relevant effects.”
> “Furthermore, we highlight unexplained deviations from the study protocol that warrant scrutiny.”

Source: [Wolff et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42903188/)

Additional sources: [Madras (2022)](https://www.nejm.org/doi/full/10.1056/NEJMe2210975)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
